Trial Profile
The evaluation of the efficacy of a switch from GnRH agonist to GnRH antagonist in prostate cancer patients who relapsed during combined androgen blockade.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 09 Sep 2014
Price :
$35
*
At a glance
- Drugs Degarelix (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 05 Sep 2014 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan record.
- 26 Jun 2014 New trial record